Cite
HARVARD Citation
Rugo, H. et al. (n.d.). HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin. European journal of cancer. pp. S41-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Rugo, H. et al. (n.d.). HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin. European journal of cancer. pp. S41-. [Online].